Optimizing gonadotrophin-releasing hormone antagonist protocols

References

• Albano C, Grimbizis G, Smitz J, Riethmuller-Winzen H, Reissmann T, VanSteirteghem A, Devroey P. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotrophin and the gonadotrophin-releasing hormone antagonist Cetrorelix. Fertility and Sterility 1998; 70: 357–359
   PubMed Web of Science ®Google Scholar
• Albano C, Platteau P, Tavaniotou A, Smitz J. Luteal phase after the use of LHRH agonist and antagonist. Infertility and Reproductive Medicine Clinics of North America 2001; 12: 163–178
   Google Scholar
• Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered ‘difficult responders˚s to GnRH agonist protocols?. Human Reproduction 1999; 14: 2959–2962
   PubMed Web of Science ®Google Scholar
• Daya S. Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer (Cochrane Review) The Cochrane Library 4. Update Software, Oxford 1999, 2001
   Google Scholar
• European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Human Reproduction 2001; 16: 644–651
   PubMed Web of Science ®Google Scholar
• European Orgalutran® Study Group, Borm G, Mannaerts B. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Human Reproduction 2000; 15: 1490–1498
   Google Scholar
• Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 1998; 13: 3023–3031
   Google Scholar
• Hughes E, Fedorkow D, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadtrophin-releasing hormone agonists prior to in vitro fertilisation and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertility and Sterility 1992; 58: 888–896
   PubMed Web of Science ®Google Scholar
• Lin Y, Kahn JA, Hillensjo T. Is there a difference in the function of granulosa-luteal cells in patients undergoing in vitro fertilization either with gonadotrophin-releasing hormone agonist or gonadotrophin-releasing hormone antagonist?. Human Reproduction 1999; 14: 885–888
   PubMed Web of Science ®Google Scholar
• Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmuller-Winzen H, Schuler A, Engel W, Diedrich K. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 2000; 264: 29–32
   PubMed Web of Science ®Google Scholar
• Nikolettos, N, Al-Hasani, S, Felberbaum, R, et al. Gonadotrophin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. European Journal of Obstetrics and Gynecology and Reproductive Biology 2001; 97: 202–207
   PubMed Web of Science ®Google Scholar
• North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertility and Sterility 2001; 75: 38–45
   PubMedGoogle Scholar
• Olivennes F, Ayoubi R, Fanchin C, Rongieres-Bertrand S, Hamamah P, Bouchard P, Frydman R. GnRH antagonist in single dose applications. Human Reproduction Update 2000; 6: 313–317
   PubMed Web of Science ®Google Scholar
• Olivennes F, Fanchin C, Rongieres-Bertand S, Bouchard P, Frydman R. GnRH antagonist in single dose applications. Infertility and Reproductive Medicine Clinics of North America 2001; 12: 119–128
   Google Scholar
• Ravhon A, Lawrie H, Lavery S, Ellenbogen A, Trew G, Winston R. A prospective, randomized controlled trial comparing the efficacy of recombinant follicle-stimulating hormone in three different in vitro fertilization protocols. Fertility and Sterility 2000; 73: 908–912
   Google Scholar
• Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Human Reproduction 1995; 10: 1974–1981
   PubMed Web of Science ®Google Scholar
• Rutherford A, Subak-Sharpe RJ, Dawson KJ, Margara RA, Franks S, Winston RM. Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone. British Medical Journal 1988; 296: 1765–1768
   PubMed Web of Science ®Google Scholar
• Wikland M, Bergh C, Borg K, Hillensjo T, Howles CM, Knutsson A, Nilsson L, Wood M. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction 2001; 18: 1676–1681
   Google Scholar